Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
26.38B
Market cap26.38B
Price-Earnings ratio
-29.48
Price-Earnings ratio-29.48
Dividend yield
Dividend yield
Average volume
2.20M
Average volume2.20M
High today
$122.47
High today$122.47
Low today
$119.09
Low today$119.09
Open price
$121.02
Open price$121.02
Volume
2.40M
Volume2.40M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$90.39
52 Week low$90.39

Stock Snapshot

Insmed Incorporated(INSM) stock is priced at $120.54, giving the company a market capitalization of 26.38B. It carries a P/E multiple of -29.48.

As of 2026-09-22, Insmed Incorporated(INSM) stock has fluctuated between $119.09 and $122.47. The current price stands at $120.54, placing the stock +1.2% above today's low and -1.6% off the high.

Insmed Incorporated(INSM) shares are trading with a volume of 2.4M, against a daily average of 2.2M.

During the past year, Insmed Incorporated(INSM) stock moved between $90.39 at its lowest and $212.75 at its peak.

During the past year, Insmed Incorporated(INSM) stock moved between $90.39 at its lowest and $212.75 at its peak.

INSM News

TipRanks 13h
Insmed: Buy Rating Reaffirmed on Arikayce Growth and Pipeline Upside with Price Target Maintained at $214

Analyst Jason Zemansky from Bank of America Securities maintained a Buy rating on Insmed and keeping the price target at $214.00. Jason Zemansky has given his...

TipRanks 2d
Insmed says FDA grants Priority Review to sNDA for Arikayce

Insmed (INSM) announced that the U.S. FDA has accepted the company’s Supplemental New Drug Application for review of Arikayce for the treatment of Mycobacterium...

Simply Wall St 7d
Is Insmed Fully Priced After Its 296% Revenue Surge?

has seen its stock reshape over the past few years, and the question now is whether the current price is supported by what the business is generating in sales....

Is Insmed Fully Priced After Its 296% Revenue Surge?

Analyst ratings

100%

of 24 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.